Abstract 1567P
Background
Long-term colorectal cancer (CRC) monitoring is common in Asia, but assessing colonoscopy effectiveness by adenoma detection rates (ADR) remains rare. The objective of this study was to evaluate the relationship between physician ADR and PCCRC incidence in sequential screening programs in order to provide up-to-date clinical evidence relevant to guiding CRC screening policies and practices.
Methods
This retrospective longitudinal observational study included participants (aged 40-74) with initial positive results and subsequent colonoscopy recruited from a community-based, multicenter, CRC screening program from January 2012 and December 2022 in Tianjin, China. ADR was defined as the proportion of colonoscopies in which at least 1 adenoma was detected. The primary outcome was PCCRC, defined as any CRC diagnosed 6 months after initial colonoscopy. ADR groups were categorized according to quartile distribution <42%, 42%-55%, 55%-64%, >64%), or dichotomized as at or above vs below the median for statistical analyses. PCCRC incidence rates were expressed as the number of events per 1000 person-years.
Results
Among 9957 included participants, 116 PCCRC cases were detected in 33881 person-years of follow-up. PCCRC incidence rates were per 1000 person-years were 4.34, 3.76, 2.62, and 2.69 from lowest to highest ADR group, respectively. ADR was significantly inversely associated with risk of PCCRC. Participants in the highest ADR group had 49% lower risk of PCCRC than low ADR group subjects (adjusted HR: 0.51, 95% CI 0.29-0.88). Multivariate-adjusted restricted cubic spline analyses identified a linear dose-response relationship between ADR and PCCRC risk.
Conclusions
Our findings show that ADR is inversely associated with risks of both PCCRC and interval PCCRC incidence, expanding the currently limited pool of data available for assessment of colonoscopy-based CRC monitoring programs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant number: 81973135), Science and Technology Commission of Shanghai Municipality (Grant number: 21XD1402600), and Tianjin Science and Technology Plan Project (Grant number: 23KPHDRC00260).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10